Clinical trial
A Randomized Controlled, Open-label, Multi-center Study With 104-week Saxagliptin or (and) Vitamin D3 Assessing Protective Effects on Beta Cell Function in Latent Autoimmune Diabetes in Adults (LADA) Treated With Metformin (and Insulin)
NCT02407899 is registered in ClinicalTrials.gov with Second Xiangya Hospital of Central South University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Controlled, Open-label, Multi-center Study With 104-week Saxagliptin or (and) Vitamin D3 Assessing Protective Effects on Beta Cell Function in Latent Autoimmune Diabetes in Adults (LADA) Treated With Metformin (and Insulin)
- Lead sponsor
- Second Xiangya Hospital of Central South University
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2015
- Completion date
- December 31, 2020
- Enrollment
- 300 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.